Market Overview

Bernstein Believes Mylan Could Offer $22/Share for Warner Chilcott, Calls Deal with Actavis More Likely

Related MYL
Mylan Wins Motion To Enjoin GlaxoSmithKline From Providing Paroxetine CR Yo Apotex; Apotex Can No Longer Supply Authorized Generic Product
Mylan (MYL) Joins the Tax-Inversion Wave
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)
Related WCRX
Actavis, Warner Chilcott Receive FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin

Bernstein analyst Aaron Gal issued a note Tuesday morning suggesting Warner Chilcott's (NASDAQ: WCRX) "willingness" for an all-share deal could cause other suitors to jump in for a possible bid. The analyst also pointed to benefits from tax synergies.

The analyst said Mylan (NYSE: MYL) could potentially offer Warner Chilcott $22 per share. Actavis's (NYSE: ACT) current bid is at $20.08 per share.

That being said, Gal believes a deal between Actavis and Warner is much closer to fruition than a Mylan deal.

Gal said Actavis could move into the $130 per share range amid the deal.

Posted-In: Analyst Color News M&A Analyst Ratings


Most Popular

Related Articles (MYL + ACT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free